Asian Journal of Transfusion Science, 2021 Familial hypercholesterolemia (FH) is characterized by an increase in plasma low-density lipoprotein-cholesterol (LDL-C) levels. It presents with tendon/skin xanthomas and premature atherosclerotic cardiovascular disease.
Daljit Kaur +7 more
doaj +2 more sources
Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B
Journal of Lipid Research, 2000 Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates ...
Klaus G. Parhofer +3 more
doaj +2 more sources
Homozygous familial hypercholesterolemia with stenosis of the left anterior descending coronary artery successfully treated with weekly low‐density lipoprotein apheresis for 16 years without percutaneous coronary intervention [PDF]
Clinical Case Reports, 2019 We successfully treated a patient with homozygous familial hypercholesterolemia (HoFH) with stable coronary arterial disease using optimal medical therapy and low‐density lipoprotein (LDL) apheresis for 16 years without percutaneous coronary intervention
Takanori Yasu +6 more
doaj +2 more sources
Preoperative Low-Density Lipoprotein Apheresis for Preventing Recurrence of Focal Segmental Glomerulosclerosis after Kidney Transplantation [PDF]
Journal of Transplantation, 2018 Background. Focal segmental glomerulosclerosis (FSGS) often develops rapidly and frequently progresses to renal failure, while the recurrence rate after kidney transplantation is 20–50%.
Akihito Sannomiya +5 more
doaj +2 more sources
Lipoprotein apheresis reduces SARS-CoV-2 S protein antibody levels in patients with familial hypercholesterolaemia after vaccination with BNT162b2 [PDF]
Atheroscler Plus, 2022 Valaiyapathi R +6 more
europepmc +2 more sources
Repeated lipoprotein apheresis and immune response: Effects on different immune cell populations [PDF]
Therapeutic apheresis and dialysis, 2022 Atherosclerosis is considered a chronic inflammation of arterial vessels with the involvement of several immune cells causing severe cardiovascular diseases.
Romy Walther +8 more
openalex +2 more sources
Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study [PDF]
Frontiers in Pediatrics, 2019 Background: Focal segmental glomerulosclerosis (FSGS) causes end stage renal disease (ESRD) in significant proportion of patients worldwide. Primary FSGS carries poor prognosis and management of FSGS patients, refractory to standard treatments or ...
Rupesh Raina +13 more
doaj +2 more sources
CPT: Pharmacometrics & Systems PharmacologyEvinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH).
Sébastien Bihorel +8 more
doaj +2 more sources
Clinical hemocompatibility of double‐filtration lipoprotein apheresis comparing polyethersulfone and ethylene‐vinyl alcohol copolymer membranes [PDF]
Artificial Organs, 2021 INTRODUCTION Activation of the complement system and leukocytes by blood-membrane interactions may further promote arteriosclerosis typically present in patients on lipoprotein apheresis. As clinical data on the hemocompatibility of lipoprotein apheresis
Detlef H. Krieter +5 more
openalex +2 more sources
Treating PAD Patients with Lipoprotein Apheresis. [PDF]
J Atheroscler ThrombHarada-Shiba M.
europepmc +3 more sources